Among anti-obesity drugs, a GLP-1 agonist called liraglutide (a subcutaneous antidiabetic drug), in addition to diet and physical exercise, demonstrated the ability to obtain a significant decrease in the size of VAT in a population of obese patients without diabetes mellitus. Here, GLP1R is linked to obesity disorder.